針對第四期非小細胞肺癌（NSCLC）患者使用Necitumumab，同時併用第一線藥物健擇、CDDP進行臨床實驗。預計招募189位在日本進行。
英文說明： The purpose of the Phase 1b portion of the study is to investigate how the body tolerates necitumumab, in combination with gemcitabine and cisplatin chemotherapy as first line treatment in participants with Stage IV squamous NSCLC and to determine the recommended dose for the subsequent Phase 2 portion of the study.
The purpose of the Phase 2 portion of the study is to evaluate the efficacy of necitumumab in combination with gemcitabine and cisplatin chemotherapy in participants with Stage IV squamous NSCLC in a first-line setting.
關於藥物Necitumumab，可以參考 https://www.lilly.co.jp/pressrelease/2013/news_2013_033.aspx
